Portfolio company
Kyverna Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This biopharmaceutical company develops chimeric antigen receptor T-cell therapies for patients with B-cell driven autoimmune diseases such as multiple sclerosis and lupus nephritis.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Abata Therapeutics
This company develops regulatory T cell therapies to treat patients with severe autoimmune and inflammatory diseases including progressive multiple sclerosis and type 1 diabetes.
PeproMene Bio
This biotechnology company develops cell therapies for patients with relapsed or refractory B-cell malignancies and autoimmune disorders.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Quell Therapeutics
This clinical-stage company develops engineered T-regulatory cell therapies for patients with autoimmune diseases, inflammatory conditions and organ transplant rejection.
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Ouro Medicines
This biotechnology firm develops T-cell engager therapies to treat patients living with chronic immune-mediated diseases.
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
Orca Bio
This company develops high-precision allogeneic cell therapies to treat patients with blood cancers and autoimmune diseases by replacing diseased immune systems with donor cells.